Patient and transplantation characteristics
| ID . | Diagnosis . | Age, y . | CD34+ dose, 106/kg . | T-cell dose, 104/kg . | Conditioning . | GVHD prophylaxis . | DLI (day) . | Acute GVHD, grade . | Day of 100% donor T-cell chimerism . | Day after HSCT of CMV analysis . | No. of CMV reactivations . | Days of CMV positivity . | IST on day of CMV analysis after HSCT . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CML | 41 | 4.22 | 2 | Flu/Cy/TBI | CsA | 63 | — | 90 | 120 | 0 | 0 | CsA 125 mg bid; Pred 10 mg qod |
| 2 | CML | 29 | 4.84 | 2 | Flu/Cy/TBI | CsA | — | — | 34 | 171 | 1 | 7 | CsA 25 mg bid; Pred 5 mg qd |
| 3 | AML | 32 | 4.36 | 2 | Flu/Cy/TBI | CsA | 45 | — | 90 | 120 | 2 | 21 | Pred 10 mg qd |
| 4 | CML | 21 | 4.86 | 2 | Flu/Cy/TBI | CsA | — | S (II) | 45 | 62 | 0 | 0 | CsA 50 mg bid; Pred 15 mg qod |
| 5 | ALL | 18 | 5.3 | 2 | Flu/Cy/TBI | CsA | — | G (IV) | 34 | 61 | 1 | 7 | Sirolimus 2.3 mg qd; Methylpred 60 mg qd |
| 6 | CML | 31 | 10 | 2 | Flu/Cy/TBI | CsA | 44 | — | 62 | 118 | 3 | 28 | CsA 75 mg bid |
| 7 | AML | 40 | 6.16 | 2 | Flu/Cy/TBI | CsA | 96 | — | 45 | 126 | 3 | 28 | CsA 100 mg bid |
| 8 | AML | 31 | 7.28 | 2 | Flu/Cy/TBI | CsA | 63 | — | 11 | 120 | 9 | 119 | CsA 100 mg bid |
| 9 | MF | 33 | 9.36 | 2 | Flu/Cy/TBI | CsA | 70 | — | 44 | 118 | 1 | 21 | CsA 50 mg bid; hydrocortisone 15 mg qd |
| 10 | ALL | 17 | 7.22 | 2 | Flu/Cy/TBI | CsA | 46 | — | 46 | 122 | 0 | 0 | CsA 75 mg bid: Pred 10 mg qod |
| 11 | AML | 30 | 5.17 | 2 | Flu/Cy/TBI | CsA | 43 | — | 43 | 84 | 0 | 0 | CsA 75 mg bid; Pred 20 mg qod |
| 12 | AML | 29 | 8.28 | 2 | Flu/Cy/TBI | CsA | — | S/L (II) | 29 | 120 | 3 | 28 | CsA 125 mg bid |
| 13 | CML | 27 | 3.91 | 2 | Flu/Cy/TBI | CsA | 63 | — | 62 | 155 | 0 | 0 | CsA 50 mg bid; Pred 10 mg qod |
| 14 | MDS | 39 | 4.27 | 2 | Flu/Cy/TBI | CsA | 55 | — | 116 | 133 | 1 | 16 | CsA 75 mg bid; Pred 20 mg qd |
| 15 | AML | 27 | 5.38 | 2 | Flu/Cy/TBI | CsA | — | S/G (II) | 36 | 63 | 1 | 7 | CsA 100 mg bid; Pred 5 mg qod |
| 16 | ALL | 32 | 5.80 | 2 | Flu/Cy/TBI | CsA | — | L/G (II) | 45 | 62 | 3 | 21 | Tacro 0.5 mg qd; Pred 5 mg qd |
| 17 | ALL | 36 | 3.36 | 2 | Flu/Cy/TBI | CsA | — | S (II) | 60 | 71 | 2 | 19 | CsA 125 mg bid |
| 18 | AML | 39 | 9.10 | 2 | Flu/Cy/TBI | CsA | — | S (II) | 30 | 82 | 0 | 0 | CsA 25 mg qd; Pred 5 mg qd |
| ID . | Diagnosis . | Age, y . | CD34+ dose, 106/kg . | T-cell dose, 104/kg . | Conditioning . | GVHD prophylaxis . | DLI (day) . | Acute GVHD, grade . | Day of 100% donor T-cell chimerism . | Day after HSCT of CMV analysis . | No. of CMV reactivations . | Days of CMV positivity . | IST on day of CMV analysis after HSCT . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CML | 41 | 4.22 | 2 | Flu/Cy/TBI | CsA | 63 | — | 90 | 120 | 0 | 0 | CsA 125 mg bid; Pred 10 mg qod |
| 2 | CML | 29 | 4.84 | 2 | Flu/Cy/TBI | CsA | — | — | 34 | 171 | 1 | 7 | CsA 25 mg bid; Pred 5 mg qd |
| 3 | AML | 32 | 4.36 | 2 | Flu/Cy/TBI | CsA | 45 | — | 90 | 120 | 2 | 21 | Pred 10 mg qd |
| 4 | CML | 21 | 4.86 | 2 | Flu/Cy/TBI | CsA | — | S (II) | 45 | 62 | 0 | 0 | CsA 50 mg bid; Pred 15 mg qod |
| 5 | ALL | 18 | 5.3 | 2 | Flu/Cy/TBI | CsA | — | G (IV) | 34 | 61 | 1 | 7 | Sirolimus 2.3 mg qd; Methylpred 60 mg qd |
| 6 | CML | 31 | 10 | 2 | Flu/Cy/TBI | CsA | 44 | — | 62 | 118 | 3 | 28 | CsA 75 mg bid |
| 7 | AML | 40 | 6.16 | 2 | Flu/Cy/TBI | CsA | 96 | — | 45 | 126 | 3 | 28 | CsA 100 mg bid |
| 8 | AML | 31 | 7.28 | 2 | Flu/Cy/TBI | CsA | 63 | — | 11 | 120 | 9 | 119 | CsA 100 mg bid |
| 9 | MF | 33 | 9.36 | 2 | Flu/Cy/TBI | CsA | 70 | — | 44 | 118 | 1 | 21 | CsA 50 mg bid; hydrocortisone 15 mg qd |
| 10 | ALL | 17 | 7.22 | 2 | Flu/Cy/TBI | CsA | 46 | — | 46 | 122 | 0 | 0 | CsA 75 mg bid: Pred 10 mg qod |
| 11 | AML | 30 | 5.17 | 2 | Flu/Cy/TBI | CsA | 43 | — | 43 | 84 | 0 | 0 | CsA 75 mg bid; Pred 20 mg qod |
| 12 | AML | 29 | 8.28 | 2 | Flu/Cy/TBI | CsA | — | S/L (II) | 29 | 120 | 3 | 28 | CsA 125 mg bid |
| 13 | CML | 27 | 3.91 | 2 | Flu/Cy/TBI | CsA | 63 | — | 62 | 155 | 0 | 0 | CsA 50 mg bid; Pred 10 mg qod |
| 14 | MDS | 39 | 4.27 | 2 | Flu/Cy/TBI | CsA | 55 | — | 116 | 133 | 1 | 16 | CsA 75 mg bid; Pred 20 mg qd |
| 15 | AML | 27 | 5.38 | 2 | Flu/Cy/TBI | CsA | — | S/G (II) | 36 | 63 | 1 | 7 | CsA 100 mg bid; Pred 5 mg qod |
| 16 | ALL | 32 | 5.80 | 2 | Flu/Cy/TBI | CsA | — | L/G (II) | 45 | 62 | 3 | 21 | Tacro 0.5 mg qd; Pred 5 mg qd |
| 17 | ALL | 36 | 3.36 | 2 | Flu/Cy/TBI | CsA | — | S (II) | 60 | 71 | 2 | 19 | CsA 125 mg bid |
| 18 | AML | 39 | 9.10 | 2 | Flu/Cy/TBI | CsA | — | S (II) | 30 | 82 | 0 | 0 | CsA 25 mg qd; Pred 5 mg qd |
The DLI dose was 107/kg. Grade II to IV GVHD is shown. Some patients who did not experience grade II to IV GVHD were on low-dose corticosteroids at the time of immunologic analysis after HSCT for adrenal insufficiency (1 patient), mild skin GVHD (5 patients), or oral GVHD after day 100 (2 patients).
CML indicates chronic myelogenous leukemia; AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; MDS, myelodysplasia; MF, myelofibrosis; Flu, fludarabine 25 mg/m2 for 5 days; Cy, cyclophosphamide 60 mg/kg for 2 days; TBI, total body irradiation at 1200 cGy; GVHD, graft-versus-host disease; DLI, donor lymphocyte infusion; CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplantation; S, skin; G, gut; L, liver; IST, immunosuppressive therapy; CsA, cyclosporine; Tacro, tacrolimus; Pred, prednisone; Methylpred, methylprednisolone; qd, once a day; bid, twice a day; qod, every other day; and —, not applicable.